CGC Webinars and Special Seminars

      

Building on the remarkable success of our pilot webinars, the CGC is continuing the webinar series sponsored by the Cancer Genomics Consortium and the University of Wisconsin Collaborative Genomics ConferenceThese lecture series focus on topics of high interest for CGC members and attendees of the UW Collaborative Genomic Conference, including implementation of new technologies in clinical genetic/genomic testing, standards and resources for interpretation of sequence and copy number variants, germline predisposition to cancer and novel approaches for detection of structural variants in constitutional and cancer samples. The CGC is currently accepting cases for the 2023 Case Conference Series.

The CGC also plans to present additional seminars on special topics throughout the year. Please look for information both on this page and in emails for these opportunities.                              




                  

               CGC Genomic Case Series sponsored by the Cancer Genomics Consortium
and the University of Wisconsin Collaborative Genomics Conference

     

Submit a Case for a Future Case Conference Webinar

                

The CGC Education committee is excited to announce a monthly case conference series offered in collaboration with the UW Collaborative Genomics Conference.

These  conferences will allow CGC members to: showcase their interesting and educational cases, promote their  clinical and research work,  consult with colleagues about challenging test results, earn CE credits at no charge through the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP), and identify collaborators with similar cases and shared clinical or research interests.

Additional benefits for trainees include winning the ’Best Case Presentation‘ award and the option to submit a case report for publication in the Cancer Genetics journal.

                                                    

September 2023 CGC Webinar:
Recommendations for Interpretation of Low Penetrance Variants and Risk Alleles

Tuesday, September 5, 2023
10:00 PM PDT / 1:00 PM EDT

                                           
                        
Matthew S. Lebo, PhD

Matthew S. Lebo, PhD


Ryan Schmidt, MD, PhD

Ryan Schmidt, MD, PhD

             

Join the co-chairs of the ClinGen Low-Penetrance / Risk Allele Work Group, Matthew S. Lebo and Ryan Schmidt, for a discussion about the  challenges surrounding the interpretation of variants at the low end of the penetrance spectrum and recommendations to improve harmonization across the molecular diagnostic community. 

Session Abstract:
Unique challenges surround the interpretation of variants at the low end of the penetrance spectrum. Classification of these variants frequently conflicts between laboratories as these variants may be associated with genetic and experimental evidence that would support a benign classification for high penetrance variants. Additionally, the reporting practices and terminology usage surrounding low penetrance variants and risk alleles vary among molecular diagnostic laboratories. Our work identifies challenges with the interpretation of variants at the low end of the penetrance spectrum and provides recommendations to improve harmonization across the molecular diagnostic community. 

Objectives:
At the end of the session, the participant will be able to:

  • Describe the objectives of the ClinGen Low Penetrance/Risk Allele Working Group
  • Discuss the value of laboratory agreement for the same alterations
  • Differentiate pathogenicity of a variant from clinical interpretation
  • Develop protocol for reporting penetrance information


CGC members are eligible to receive P.A.C.E. Continuing Education credit for attending this webinar. 

To become a member or learn more about the benefits of CGC membership, CLICK HERE



          

February 2023 CGC Webinar: CGC 2022 Annual Meeting Poster Winners

Tuesday, February 21, 2023

                                         
                        

Copy number alterations are commonly seen in childhood brain tumors and may help predict survival

Sharon FreshourSharon Freshour is a PhD candidate in the Human and Statistical Genetics program at Washington University in St. Louis. She graduated from St. Edward’s University in 2016 with a B.S. in Mathematics. She is interested in utilizing next generation sequencing and bioinformatic analysis to understand the genomic landscape of cancer and how it relates to treatment response. Her current research topics include using whole genome sequencing to explore copy number alterations in childhood brain tumors and using single cell RNA sequencing to understand mechanisms of response to checkpoint inhibitor treatment in a mouse model of bladder cancer.

Single-cell RNA sequencing and co-occurring cellular state analysis of high-grade serous ovarian cancer

Nicolas SemenkovichNicholas Semenkovich is a physician scientist and clinical fellow in Endocrinology, Metabolism, and Lipid Research at Washington University in St. Louis. He is currently a postdoctoral scholar with Dr. Aadel Chaudhuri working on cell-free DNA. He is developing machine learning methods to analyze cell free DNA and provide insights into chronic and metabolic disease (in addition to oncology). Prior to his fellowship, Nicholas completed an Internal Medicine residency at the Brigham and Women’s Hospital. He completed MD/PhD training at Washington University with Dr. Jeff Gordon exploring the impact of the gut microbiota on host epigenetic signaling, and his undergrad at MIT in Computer Science.

ABSTRACT: Brain and central nervous system tumors are the most common form of solid tumor cancers and the second most common cancer overall among children. Although advances have been made in understanding the genomics of childhood brain tumors, the role of copy number alterations (CNAs) has not been fully characterized. While genomes of childhood brain tumor patients are generally considered to be relatively stable diploid genomes, analysis of a subset of pretreatment diagnostic samples from a cohort of 84 deceased patients with a variety of brain cancer diagnoses from Washington University revealed widespread alterations, suggesting CNAs may play a larger role in childhood brain tumors than originally thought. Low-pass whole genome sequencing of these samples showed that 75 out 84 patients had detectable presence of CNAs (Percentage genome altered (total altered bp/3.2?10^9 bp)?100%: mean 16%, median 7%, range 0-50%). Preliminary results examining correlations between the percentage of the genome that was copy number altered and event free or overall survival indicated that CNA percentage may have prognostic value. To explore these results further, 200 additional samples from the Pediatric Brain Tumor Atlas curated by The Children’s Brain Tumor Network were analyzed, revealing similar trends in copy number alteration. Additionally, alterations that were recurrently detected across samples were identified and similar analyses were performed to determine whether certain alterations or patterns of alteration could be predictive of event free or overall survival. 219 alterations were identified as significantly recurrently mutated and of these, 22 alterations were associated with changes in overall survival.


    

ABSTRACT:High-grade serous carcinoma (HGSC) is the most lethal subtype of ovarian cancer, and a majority of patients are diagnosed at advanced stages. One standard-of-care is neoadjuvant chemotherapy followed by cytoreductive surgery, however up to 80% of HGSC patients develop recurrent disease. There exists a critical need to better understand the features of this tumor microenvironment that may highlight potential therapeutic targets, help stratify chemotherapy responders from non-responders, and uncover novel cell states that may serve as prognostic or predictive biomarkers.

We obtained multiple biopsies from five patients with advanced-stage HGSC, both pre- and post-treatment, and analyzed these samples using single-cell RNAseq. We identified 20 distinct transcriptional clusters of cells, including a well-defined tumor subset enriched for EPCAM and KRT8. We annotated each cluster using known marker genes, and additionally validated these data through genome-wide copy number and developmental maturity analyses.

We then performed transcriptome deconvolution to identify co-occurring transcriptional states using EcoTyper. We then performed bulk RNAseq on paired pre- and post-treatment tumor biopsies from 23 HGSC patients. Applying our fingerprints of ecotypes from the scRNA-seq data, we identified multiple distinct transcriptional states within the pre- and post-treatment HGSC tumor microenvironment, which were enriched for distinct co-occurring states comprised of multiple immunologic lineages, including CD4 T and NK cell states. We plan to validate these ecotypes using spatial transcriptomics and compare clinical outcomes across transcriptional states to determine the potential prognostic or predictive implications of our discoveries.

    


                                        

January 2023 CGC Webinar: CGC 2022 Annual Meeting Poster Winners

Tuesday, January 17, 2023

                                        
                        

Cell-type-specific genotypic interpretation
in the human breast

Axel Hauduc is a Ph.D. candidate in the Hirst Lab at the University of British Columbia, Canada. Axel grew up in the Seattle area and attended the University of California, Berkeley for his bachelor’s degree in Molecular & Cell Biology (Neurobiology emphasis) and French. While at Cal, Axel was a research intern at the Gladstone Institutes at the University of California, San Francisco, and the Allen Institute for Brain Science in Seattle, working mainly in neurobiology and mouse models of Alzheimer’s disease. After graduation, Axel was drawn to genomics for its potential to transform the huge influxes of genetic data generated each day into deeper understanding of biology and potential therapies. Axel enrolled in the Genome Science and Technology program at UBC’s Michael Smith Laboratories in September 2019 and joined the Hirst Lab in January 2020. At the Hirst Lab, Axel’s research focuses on interpreting cell-type-specific epigenetic datasets and characterizing the interactions between various epigenetic marks and genetic variants in human breast tissue.

Standardized assessment of Oncogenicity and clinical significance of NTRK fusions

Dr. Jason Saliba is is a Senior Scientist in the Griffith Laboratory at the Washington University School of Medicine with over 10 years of experience in cancer research. Dr. Saliba’s research is focused on the development and improvement of protocols, classification guidelines, and training methods related to the curation and interpretation of clinically significant information advancing precision medicine in cancer. He was the first full-time editor of the Clinical Interpretation of Variants in Cancer (CIViC) knowledgebase, which is an open access, open source, community-driven web resource for the curation of somatic variant evidence. Dr. Saliba founded and chairs the Pediatric Cancer Curation Advancement Subcommittee (PCCAS), which is a collaboration between CIViC, the ClinGen Pediatric Cancer Taskforce, and Disease Ontology, with the goal of enhancing pediatric cancer curation and the public dissemination of high-quality childhood focused interpretations. He serves as the Coordinator of the ClinGen Somatic Cancer Clinical Domain Working Group, its Taskforces and Somatic Cancer Variant Curation Expert Panels. 

ABSTRACT: Understanding the interplay between genetic and epigenetic states is fundamental to the study of development and mechanisms of disease. Most studies that have explored this interplay have leveraged population-scale genotype surveys to associate genetic polymorphisms with epigenetic states in whole blood or other heterogenous tissue types. However, epigenetic states are cell-type specific, raising the possibly of cell-type-specific genetic/epigenetic relationships that could drive specific functional states and disease predisposition. To address this question, I analyzed enriched regions for six histone modifications across four functionally distinct human breast cell types from eight phenotypically normal women to identify genetic variants that influence cell-type-specific epigenetic states. I define the incidence by cell-type and histone mark of these interactions across breast cell types, terming them cis histone binary trait loci, or cis-hBTLs, and prioritize them through interrogation of matched gene expression datasets. Variants were prioritized based on altered expression of associated genes and these were found to be enriched in genes and long noncoding RNAs implicated in breast carcinogenesis. A subset of these variants was then validated in epithelial breast cell lines. My analysis thus suggests that genotype is variably interpreted across functionally distinct breast cell subtypes and that this variation may have implications for understanding genetic influences on breast cancer initiation and progression.


    

ABSTRACT:Gene fusions involving the neurotrophic receptor tyrosine kinase genes (NTRK1, NTRK2, and NTRK3) are well established oncogenic drivers in a broad range of pediatric and adult tumors, and important diagnostic and therapeutic markers predicting response to FDA approved kinase inhibitors. Accurate interpretation of the clinical significance of NTRK-fusions is a high priority for diagnostic laboratories, but remains challenging and time consuming given the rapid pace of new data accumulation, the diversity of fusion partners and tumor types, and heterogeneous and incomplete information in variant knowledgebases.

The ClinGen NTRK-Fusions Somatic Cancer Variant Curation Expert Panel (SC-VCEP) was formed to systematically address these challenges and create a resource of high-quality clinically significant assertions in the CIViC knowledgebase to support clinicians, researchers, patients and their families in making accurate interpretations and informed treatment decisions for NTRK-fusion driven tumors. As the first ClinGen VCEP formed to focus on somatic alterations, our group of researchers and clinicians has pioneered an evidence-based classification system for assessing oncogenicity and functional validity of NTRK-fusions (Oncogenic, Likely oncogenic, Unknown significance, and Benign) through the compilation of key fusion element annotations (e.g., fusion transcript structure, cancer association, and clinical validity). Additionally, the NTRK-Fusions SC-VCEP has developed specifications of AMP/ASCO/CAP rules to determine the diagnostic, prognostic and predictive significance of NTRK-fusions. Finally, detailed aggregation and analysis of NTRK-fusions represented in public fusion databases has allowed us to determine gaps and prioritize curation activities to efficiently and comprehensively curate NTRK-fusion clinical evidence, apply interpretation rules, and create high-quality publicly available clinical interpretations.

    
      

Registration Instructions

1. Register for the Zoom Webinar at: Information about the next CGC webinar coming soon!
2. Once you have registered, you will receive a confirmation e-mail with the Zoom link for the day of the webinar.

3. On the day of the webinar, click on the link in the registration e-mail to join the webinar.